A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults

400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase

1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase

Age\<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age\>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4

5µg/kg/d (SC) D6 until neutrophils \> 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4

40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1

40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3

2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3

300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years

60 mg/m2 per os, D1 to D14, interphase